Even if it does not look like the Author is crowning NGAL as the winner as the “one-and-only-biomarker” for AKI:)
One of the reasons for this is the large variation on cut-off’s used… well – that we can change easily – in a jiffy 🙂 … it’s just a matter of Alere/abbott et al using the RIGHT cutoff-value (250 ng/ml)
Anyway – the most important point made in the Presentation is; that in spite of 40 years of intense research, researchers and scientists are still struggling to expand the “window of opportunity” for satisfactory treatment of AKI.. – Because – as we all know Therapies will only work if the patient is diagnosed rapidly and correctly
Read the article on AKI here.
